Application of piperidine acid oxidase in liver cancer treatment
By studying the expression level and function of piperidinate oxidase (PIPOX), a pharmaceutical composition used to inhibit the migration and invasion of liver cancer cells has been developed, which has solved the problem of limited treatment methods for liver cancer and significantly improved the survival rate and quality of life of patients.
Patent Information
- Application Number
- CN202411177136.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-11-22
AI Technical Summary
The treatment methods of liver cancer are limited, with low early diagnosis and high recurrence and metastasis, resulting in low survival rates in patients and lack of effective biomarkers and therapeutic targets.
By studying the expression levels and functions of piperidinate oxidase (PIPOX), PIPOX overexpression vectors and inhibitors are developed to inhibit the migration and invasion of liver cancer cells, and combined with inhibitors of the mesenchymal cell marker Snail, prepared A pharmaceutical composition for the treatment of liver cancer.
PIPOX significantly inhibits the migration and invasion ability of liver cancer cells, prolongs the overall survival and disease-free survival of patients, provides new diagnostic and therapeutic targets, and improves the quality of survival of liver cancer patients.
Smart Images

Figure CN118987225A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the field of biotechnology, and in particular to application of pipecolic acid oxidase in the treatment of liver cancer. Background Art
[0002] Liver cancer is one of the most common and highly malignant tumors, and its incidence has been on a continuous upward trend in recent years. Due to its low early diagnosis rate and poor prognosis in the late stage, the mortality rate related to liver cancer remains high, ranking fourth among all tumor types. Primary liver cancer is morphologically divided into hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Hepatocellular carcinoma accounts for about 80%-90% of primary liver cancer, and intrahepatic cholangiocarcinoma accounts for about 10-15%. At present, the treatment methods for liver cancer are still very limited, mainly including surgical resection, liver transplantation, radiofrequency ablation, radiotherapy, chemotherapy, immunotherapy, etc. However, the 5-year survival rate of liver cancer patients is still low, mainly due to the recurrence and metastasis of liver cancer.
[0003] Pipecolic acid oxidase (PIPOX) belongs to the oxidoreductase family. It is an important metabolic enzyme in the lysine metabolic pathway and an important sarcosine metabolic enzyme. It can also mediate the protective mechanism against hydrogen peroxide stress in cells and inhibit hydrogen peroxide-induced cell death. Existing studies have shown that PIPOX plays a regulatory role in the occurrence and progression of various cancers such as prostate cancer, breast cancer, and thyroid cancer. For example, PIPOX is a tumor suppressor factor for prostate cancer, which can inhibit the invasive ability of prostate cancer cells by improving sarcosine metabolism; PIPOX is a tumor suppressor factor for breast cancer, and its low expression is associated with shorter overall survival and disease-free survival of patients; PIPOX is a carcinogen for thyroid cancer, and its high expression is associated with poor prognosis of patients.
[0004] However, the role of PIPOX in liver cancer has not been reported yet. Therefore, it is necessary to study the regulatory mechanism of PIPOX in the occurrence and development of liver cancer and enrich new diagnostic or prognostic biomarkers and therapeutic targets to improve the survival rate of liver cancer patients and improve the quality of life of patients. Summary of the invention
[0005] The amino acid sequence of pipecolic acid oxidase (PIPOX) is: maaqkdlwdaivigagiqgcftayhlakhrkrillleqfflphsrgsshgqsriirkayledfytrmmhecyqiwaqleheagtqlhrqtgllllgmkenqelktiqanlsrqrvehqclsseelkqrfpnirlprgevglldnsggviyaykalralqdairqlggivrdgekvveinpgllv tvkttsrsyqakslvitagpwtnqllrplgiemplqtlrinvcywremvpgsygvsqafpcflwlglcphhiyglptgeypglmkvsyhhgnhadpeerdcpt artdigdvqilssfvrdhlpdlkpepaviescmytntpdeqfildrhpkydnivigagfsghgfklapvvgkilyelsmkltpsydlapfrisrfpslgkahl.
[0006] In order to study the role and regulatory mechanism of PIPOX in the development of liver cancer, the inventor's team conducted a series of experimental studies. By comparing the expression differences of PIPOX in liver cancer tissues and adjacent tissues of clinical patients, it was confirmed that PIPOX is of great significance in the development of liver cancer and can be used for the diagnosis of liver cancer. In the patient prognosis analysis, liver cancer patients in the low-expression group of PIPOX showed a shorter overall survival and disease-free survival compared with the high-expression group, suggesting that PIPOX may play a certain biological function in the progression of liver cancer. In addition, the results of in vitro cell experiments and in vivo animal experiments have confirmed that PIPOX can significantly inhibit the migration and invasion of liver cancer cells.
[0007] In terms of mechanism research, the inventor team found that PIPOX can promote the mRNA and protein expression of the epithelial cell marker E-cadherin during the epithelial-mesenchymal transition (EMT) process, while inhibiting the mRNA and protein expression of mesenchymal cell markers (N-cadherin, vimentin, Snail). In this regard, experiments have found that combining the PIPOX overexpression vector with the inhibitor that knocks down Snail can further inhibit the migration and invasion of liver cancer cells.
[0008] Therefore, combined with the above functional experimental results and mechanism studies, it was confirmed that PIPOX can play an inhibitory role in the process of liver cancer metastasis, and therefore can be used as a potential drug target for the treatment of liver cancer.
[0009] Based on the relevant research on the physiological function of PIPOX in the progression and metastasis of liver cancer, the purpose of the present invention is to provide the application of pipecolic acid oxidase in the treatment of liver cancer. Specifically, the present invention is achieved by the following technical solutions:
[0010] One application of PIPOX provided by the present invention is the use of an agent capable of increasing the expression level of PIPOX in the preparation of a drug for treating liver cancer. In this technical solution, the agent capable of increasing the expression level of PIPOX can be an overexpression vector of PIPOX.
[0011] Another application of PIPOX provided by the present invention is the use of an agent capable of increasing the expression level of PIPOX in the preparation of a drug for inhibiting the migration and invasion of liver cancer cells.
[0012] The present invention also provides a combined use of PIPOX and a mesenchymal cell marker. Specifically, an agent that can increase the expression level of PIPOX is used in combination with a mesenchymal cell marker inhibitor to prepare a drug for treating liver cancer, or a drug for inhibiting the migration and invasion of liver cancer cells, wherein the mesenchymal cell marker inhibitor is at least one of siRNA, sgRNA, small molecule inhibitors, and compounds with a mesenchymal cell marker as a target gene, and the mesenchymal cell marker is at least one of N-cadherin, vimentin, and Snail.
[0013] The present invention also provides a pharmaceutical composition for treating or inhibiting the migration and invasion of liver cancer cells, wherein the pharmaceutical composition comprises an overexpression vector of PIPOX and a pharmaceutically acceptable adjuvant.
[0014] In some preferred embodiments, pharmaceutically acceptable excipients include carriers, diluents, fillers, binders, wetting agents, disintegrants, emulsifiers, solubilizers, osmotic pressure regulators, surfactants, coating materials, colorants, pH regulators, antioxidants, bacteriostats or buffers.
[0015] Furthermore, the pharmaceutical composition also includes an inhibitor for inhibiting the expression level of a mesenchymal cell marker, wherein the inhibitor is at least one of siRNA, sgRNA, a small molecule inhibitor, and a compound with the mesenchymal cell marker as a target gene.
[0016] In some preferred embodiments, the combined pharmaceutical composition is a combination of two separate preparations, which can be administered simultaneously or sequentially.
[0017] Furthermore, the mesenchymal cell marker is at least one of N-cadherin, vimentin, and Snail.
[0018] Furthermore, the mesenchymal cell marker is Snail, and the inhibitor of Snail is siRNA with a sequence as shown in SEQ ID NO.1, wherein the sequence SEQ ID NO.1 is CCACTCAGATGTCAAGAAGTA.
[0019] The present invention also provides an application of a reagent for quantitatively detecting PIPOX in preparing a product for diagnosing liver cancer or predicting the prognosis of liver cancer.
[0020] The present invention also provides a product for diagnosing liver cancer or predicting the prognosis of liver cancer, the product comprising:
[0021] A collection unit, used to obtain the expression level of PIPOX;
[0022] The analysis unit is used to analyze the diagnosis or prognosis prediction results of liver cancer based on the expression level of PIPOX.
[0023] In one or more embodiments, the product is a kit, which includes a reagent for quantitatively detecting PIPOX. In some embodiments, the reagent for quantitatively detecting PIPOX includes primers for amplifying PIPOX. In some preferred embodiments, the primers for amplifying PIPOX include the following primer pairs:
[0024] Forward primer: 5'-AGCGCACAATCCTCCTCTTT-3' (SEQ ID NO. 2)
[0025] Reverse primer: 5'-GTAATCCAGTCTGCCAGAGGTT-3' (SEQ ID NO. 3)
[0026] In some embodiments, the kit further comprises a liver tissue RNA extraction reagent and a reverse transcription reaction system. The RNA extraction reagent is Trizol reagent, and the reverse transcription reaction system comprises reverse transcriptase, buffer, RNase inhibitor, Oligo, dNTPs, etc.
[0027] The present invention also provides the use of PIPOX in screening candidate drugs for adjuvant treatment of liver cancer, wherein the use is carried out using in vitro liver cancer cells or tissues.
[0028] Compared with the prior art, the present invention has the following advantages and beneficial effects:
[0029] 1. The present invention finds that the expression of PIPOX in liver cancer tissue is significantly lower than that in adjacent tissues at both the protein level and the mRNA level, indicating that PIPOX can be used for liver cancer diagnosis. In addition, compared with liver cancer patients in the PIPOX low expression group, liver cancer patients in the PIPOX high expression group have a longer overall survival and disease-free survival, indicating that PIPOX can be used to evaluate the prognosis of liver cancer patients;
[0030] 2. The present invention constructs PIPOX into a lentiviral vector to construct a liver cancer cell line that stably overexpresses the gene, and finds that after PIPOX is overexpressed, the migration and invasion abilities of the liver cancer cells are significantly inhibited; at the same time, the present invention also constructs a liver cancer cell line that stably knocks out the gene, and finds that after PIPOX is knocked out, the migration and invasion abilities of the liver cancer cells are significantly enhanced, indicating that PIPOX has an inhibitory effect on the migration and invasion abilities of liver cancer cells, and PIPOX can be used as a therapeutic target in the treatment of liver cancer;
[0031] 3. The present invention constructs a nude mouse tumor tail vein injection lung metastasis model, and examines the effect of PIPOX on the invasion and metastasis of liver cancer cells in nude mice at the in vivo level, proving that PIPOX has a significant inhibitory effect on the invasion and metastasis of liver cancer cells;
[0032] 4. The present invention verifies that overexpression of PIPOX can inhibit the EMT process of liver cancer cells, and knocking out PIPOX can promote the EMT process of liver cancer cells. Based on this finding, by simultaneously overexpressing PIPOX and knocking down Snail, the inhibitory effect on the EMT process of liver cancer cells can be enhanced, thereby further reducing the migration and invasion of cancer cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] The drawings described herein are used to provide a further understanding of the embodiments of the present invention, constitute a part of this application, and do not constitute a limitation of the embodiments of the present invention. In the drawings:
[0034] Figure 1 The results of the difference in PIPOX expression in liver cancer tissue and adjacent tissue of liver cancer patients in a specific embodiment of the present invention are shown, wherein (a) is the relative expression of PIPOX protein in liver cancer tissue and adjacent tissue detected by immunohistochemical staining of tissue samples of patients from West China Hospital; (b) is the relative expression of PIPOX mRNA in liver cancer tissue and adjacent tissue analyzed based on the TCGA database;
[0035] Figure 2The figures show the correlation between the PIPOX protein expression level or mRNA expression level in liver cancer patients and the overall survival and disease-free survival of liver cancer patients in a specific embodiment of the present invention, wherein (a) and (b) are Kaplan-Meier survival curves based on the clinical data of West China Hospital to analyze the relationship between the PIPOX protein expression level and the overall survival and disease-free survival of liver cancer patients; (c) and (d) are Kaplan-Meier survival curves based on TCGA data to analyze the relationship between the PIPOX mRNA expression level and the overall survival and disease-free survival of liver cancer patients;
[0036] Figure 3 The expression of PIPOX protein in liver cancer cell lines stably overexpressing and knocking out PIPOX constructed in the specific embodiments of the present invention, wherein (a) is the detection result of PIPOX protein in SNU449 and LM9 liver cancer cell lines after overexpressing PIPOX; (b) is the detection result of PIPOX protein in SK-Hep1 liver cancer cell line after knocking out PIPOX;
[0037] Figure 4 The results of Transwell cell migration and invasion assays of (a) the SNU449 liver cancer cell line after overexpression of PIPOX, (b) the LM9 liver cancer cell line after overexpression of PIPOX, and (c) the SK-Hep1 liver cancer cell line after knocking out PIPOX in specific embodiments of the present invention are shown;
[0038] Figure 5 The effects of overexpression and knockout of PIPOX on tumor lung metastasis in nude mice in a specific embodiment of the present invention are shown, wherein (a) and (c) are the bioluminescent signal intensity of the lungs of nude mice detected by a living imaging device; (b) and (d) are the H&E staining of lung tissue sections to count the number of metastatic foci in the lungs of nude mice;
[0039] Figure 6 The expression levels of epithelial-mesenchymal transition (EMT) process-related markers in liver cancer cells overexpressing and knocking out PIPOX are shown by real-time fluorescence quantitative PCR and protein immunoblotting in a specific embodiment of the present invention, wherein (a) and (b) are the relative mRNA expression levels of EMT-related markers in liver cancer cells overexpressing and knocking out PIPOX detected by RT-qPCR; (c) and (d) are the protein expression levels of EMT-related markers in liver cancer cells overexpressing and knocking out PIPOX detected by protein immunoblotting;
[0040] Figure 7It is shown that in a specific embodiment of the present invention, after overexpressing PIPOX and then further knocking down the expression of Snail by siRNA, the migration and invasion abilities of each group of cells (LM9 Vector+siNC, LM9 OE-PIPOX+siNC, LM9 Vector+siSnail, LM9 OE-PIPOX+siSnail) were detected by conducting Transwell cell migration and invasion experiments. DETAILED DESCRIPTION
[0041] In order to make the objectives, technical solutions and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments and drawings. The exemplary embodiments of the present invention and their description are only used to explain the present invention and are not intended to limit the present invention.
[0042] The technology involved in the present invention is a conventional cell biology technology. The reagents and reaction conditions involved can be reasonably selected according to the experience of those skilled in the art unless otherwise specified. The reagents and consumables involved are ordinary products available on the market, and the detection methods and instruments involved are well known and mastered by those skilled in the art. Unless otherwise specified, the experimental methods in the examples adopt existing experimental method steps and are strictly performed in accordance with the instructions of the kit manufacturer.
[0043] In each embodiment of the present invention, with the approval of the Ethics Review Committee of West China Hospital, written informed consent was provided to each patient according to the policy of the committee. After the patient was fully informed and signed the informed consent, surgical resection samples of 227 patients with hepatocellular carcinoma who received surgical treatment in West China Hospital, Chengdu, China from 2009 to 2013 (liver resection, the patient did not receive any preoperative treatment) were collected, and all samples were confirmed by postoperative pathological examination results. A total of 60 patients had both liver cancer tissue samples and paired paracancerous tissue samples for analyzing the expression difference of PIPOX protein between liver cancer tissue and paired paracancerous tissue. In addition, the prognostic information of 132 patients was also collected for further analysis of the relationship between the expression level of PIPOX protein and the prognosis (including overall survival and disease-free survival) of these patients after liver resection.
[0044] In each embodiment of the present invention, human liver cancer cell lines HCCLM9 and SK-Hep1 were purchased from the cell bank of Shanghai Institute of Biological Sciences, Chinese Academy of Sciences, and human liver cancer cell line SNU449 was purchased from the American Type Culture Collection (ATCC Cell Bank). After recovery, HCCLM9, SNU449 and SK-Hep1 cell lines were placed in a constant temperature cell culture incubator at 37°C and 5% CO2 for culture. The complete culture medium was a high-glucose DMEM culture medium containing 10% fetal bovine serum and 1% penicillin-streptomycin double antibody, and the culture medium was replaced every 2-3 days. When the cell growth density reached 80%, the cells were digested with trypsin and subcultured. Cells in the logarithmic growth phase are generally used for experiments.
[0045] In each embodiment of the present invention, SPSS22.0 and GraphPad Prism 9.0 software were used to perform statistical analysis on the data. The continuous measurement data between the two groups were statistically analyzed using the t test, and the continuous measurement data between the three groups were statistically analyzed using the One-way ANOVA with Tukey's post hoc test. P<0.05 indicated that the difference was statistically significant.
[0046] [Example 1]
[0047] In this example, the expression difference of PIPOX in liver cancer tissues and adjacent tissues of clinical patients was analyzed.
[0048] The experimental results are as follows Figure 1 As shown in (a), the expression levels of PIPOX protein in paired liver cancer tissues and adjacent cancer tissues of 60 liver cancer patients from West China Hospital, as well as in unpaired 227 liver cancer tissues and 108 adjacent cancer tissues were detected by immunohistochemical staining of tissue samples. The results showed that the expression level of PIPOX protein in liver cancer tissues was significantly lower than that in adjacent cancer tissues (P<0.0001, P<0.0001).
[0049] In addition, by combining the TCGA database analysis, the expression levels of PIPOX mRNA in paired liver cancer tissues and adjacent tissues of 50 liver cancer patients, as well as the expression levels of PIPOX mRNA in unpaired 371 liver cancer tissues and 50 adjacent tissues were compared. The results also showed that compared with adjacent tissues, the expression level of PIPOX mRNA in liver cancer tissues was lower (P<0.0001, P<0.0001). The experimental results are shown in Figure 1 (b).
[0050] The above experiments all indicate that PIPOX plays an important role in the occurrence and development of liver cancer and can be used for the diagnosis of liver cancer.
[0051] [Example 2]
[0052] In this example, based on the clinical patient data of West China Hospital and TCGA data, Kaplan-Meier survival curves were used to analyze the correlation between the PIPOX protein expression level or mRNA expression level in liver cancer patients and the overall survival and disease-free survival of liver cancer patients.
[0053] In this example, 132 liver cancer patients from West China Hospital were divided into two groups based on the median value of the relative expression of PIPOX protein: a PIPOX protein high expression group (n=66) and a PIPOX protein low expression group (n=66) for prognostic analysis.
[0054] like Figure 2 (a) and Figure 2 (b) shows the Kaplan-Meier survival curve, which shows that the liver cancer patients in the low PIPOX protein expression group were significantly associated with shorter overall survival (P=0.0003) and shorter disease-free survival (P=0.0005) compared with the liver cancer patients in the high PIPOX protein expression group.
[0055] Similarly, the inventors divided the 308 liver cancer patients included in the TCGA data into two groups according to the optimal cutoff value of the relative expression of PIPOX mRNA: a PIPOX mRNA high expression group (n=252) and a PIPOX mRNA low expression group (n=56). The Kaplan-Meier survival curve showed that compared with the liver cancer patients in the PIPOX mRNA high expression group, the liver cancer patients in the PIPOX mRNA low expression group were significantly associated with a shorter overall survival (P=0.0007) and a shorter disease-free survival (P=0.0165). The experimental results are shown in Figure 2 (c) and Figure 2 (d).
[0056] The above experiments show that the protein or mRNA expression level of PIPOX can be used as an ideal prognostic marker for liver cancer patients. Therefore, the product capable of detecting the expression level of PIPOX is used to prepare a detection reagent, such as a kit, which can be used to evaluate the prognosis of liver cancer.
[0057] [Example 3]
[0058] In this example, firstly, a liver cancer cell line stably overexpressing PIPOX and a liver cancer cell line stably knocking out PIPOX were constructed.
[0059] (1) Construction of overexpression cell line: A liver cancer cell line stably overexpressing PIPOX was constructed by lentiviral infection. PIPOX overexpression lentivirus (OE-PIPOX) and negative control empty vector lentivirus (Vector) were purchased from Shanghai Gene Gene Technology Co., Ltd. LM9 and SNU449 liver cancer cell lines were selected for the establishment of overexpression stable transfection lines. Lentivirus infection and purine screening process: First, LM9 cells and SNU449 cells in the logarithmic growth phase were inoculated into 12-well plates. When the cell growth density reached about 40% to 50%, the PIPOX overexpression lentivirus and negative control empty vector lentivirus were taken out and thawed on ice. During infection, the old culture medium was discarded, washed with PBS, and 500 μL of fresh complete culture medium was added to the well plate. Then, the required volume of virus solution was calculated according to the optimal virus infection multiplicity and virus titer of each cell line, and added to the culture medium and gently mixed. After 24 hours of virus solution infection, fresh complete culture medium was replaced. After 72 hours, the cells were cultured in complete medium containing puromycin (2 μg / mL). The cell status was checked every day, and the concentration of puromycin was adjusted in time according to the cell death. After 7 days of puromycin selection, the expression level of PIPOX protein in the cell line was detected by protein immunoblotting to identify whether PIPOX was stably overexpressed. Finally, LM9 and SNU449 liver cancer cell lines that stably overexpressed PIPOX were selected for subsequent experiments.
[0060] (2) Construction of knockout cell line: CRISPR / Cas9 was used to construct a liver cancer cell line with stable knockout of PIPOX. Based on the design principle of sgRNA, two sgRNA sequences that can target the PIPOX gene were designed, named sgPIPOX-1 and sgPIPOX-2. The sequences are shown in Table 1.
[0061] Table 1
[0062]
[0063] The sgPIPOX-1 and sgPIPOX-2 lentiviruses and negative control lentiviruses involved were purchased from Beijing Qingke Biotechnology Co., Ltd. (the vector is LentiCRISPR v2-Puro). The SK-Hep1 liver cancer cell line was selected for the establishment of a knockout stable strain. The lentiviral infection, purine screening and identification process were the same as above. Finally, the SK-Hep1 liver cancer cell line with stable knockout of PIPOX was screened for subsequent experiments.
[0064] In this example, the expression of PIPOX protein in liver cancer cells after overexpression and knockout of PIPOX was detected by Western blotting. Figure 3As shown in (a), the results of western blot showed that compared with the negative control group (SNU449 Vector and LM9 Vector), the expression level of PIPOX protein in SNU449 cells (SNU449 OE-PIPOX) and LM9 cells (LM9 OE-PIPOX) in the PIPOX overexpression group was significantly increased. At the same time, compared with the negative control group (SK-Hep1sgNC), the expression level of PIPOX protein in SK-Hep1 cells (SK-Hep1 sgPIPOX-1 and SK-Hep1 sgPIPOX-2) in the PIPOX knockout group was significantly reduced. The experimental results are shown in Figure 3 (b).
[0065] The above results indicate that the liver cancer cell line with stable overexpression / knockout of PIPOX was successfully constructed and can be used for cell experiments and animal experiments.
[0066] [Example 4]
[0067] In this example, Transwell cell invasion and migration experiments were performed using the liver cancer cell lines stably overexpressing and knocking out PIPOX constructed in Example 3. The experimental method is as follows:
[0068] (1) Transwell cell invasion assay. First, place the Transwell chamber into a 24-well plate. Mix the matrix gel and serum-free medium precooled at 4°C in a ratio of 1:6 and spread evenly on the upper chamber of the chamber. Spread 30 μL in each chamber and place it in a 37°C constant temperature cell culture incubator for 2 h to wait for it to solidify. Take the cells in the logarithmic growth phase, resuspend the cells in serum-free medium, count and adjust the cell suspension concentration to 2×10 5 After that, take 200 μL of cell suspension (4×10 4 10 cells) were inoculated in the upper chamber of a chamber covered with matrix gel (each group was set up with 3 replicates), and 600 μL of complete culture medium was added to the lower chamber of the chamber. The 24-well plate was then placed in a constant temperature cell culture incubator at 37°C and 5% CO2 for continued culture. After about 48 hours (the time required for each cell type was different and needed to be adjusted according to the characteristics of the cells), the culture medium in the upper chamber was discarded, and the cells and matrix gel in the upper chamber were gently wiped off with a cotton swab. After washing with PBS, the cells were fixed with 4% paraformaldehyde for 1 hour, washed with PBS, and stained with 0.1% crystal violet stain for 30 minutes. The residual crystal violet was then washed with PBS, and the cells were placed in an oven for drying. The chambers were photographed using an inverted microscope, and 5 fields of view were randomly selected in each chamber. The stained cells were counted using Image J software, and the average value was calculated.
[0069] (2) Transwell cell migration assay: No matrix gel was added to the upper chamber of the Transwell chamber, and the cell suspension concentration was adjusted to 1×105 The other steps were the same as those in the above cell invasion assay.
[0070] The experimental results are as follows Figure 4 As shown in (a)-(c), the results of Transwell invasion assay showed that compared with the respective negative control groups, the number of LM9 cells and SNU449 cells that overexpressed PIPOX and passed through the chamber coated with Matrigel was significantly reduced (P<0.05), while the number of SK-Hep1 cells that knocked out PIPOX and passed through the chamber coated with Matrigel was significantly increased (P<0.05). At the same time, the results of Transwell migration assay showed that compared with the respective negative control groups, the number of SNU449 cells and LM9 cells that overexpressed PIPOX and passed through the chamber was significantly reduced (P<0.05), while the number of SK-Hep1 cells that knocked out PIPOX and passed through the chamber was significantly increased (P<0.05).
[0071] The above experimental results show that overexpression of PIPOX can significantly inhibit the invasion and migration of liver cancer cells, while knocking out PIPOX can significantly enhance the invasion and migration of liver cancer cells. Therefore, PIPOX can be used as a therapeutic target for inhibiting the metastasis of liver cancer cells and applied to the treatment of liver cancer, so that reagents that can overexpress the expression level of PIPOX can be used to prepare drugs for treating liver cancer, or for preparing drugs that inhibit the migration and invasion of liver cancer cells.
[0072] [Example 5]
[0073] In this example, it was verified in vivo whether PIPOX has an effect on the invasion and migration of liver cancer.
[0074] First, a nude mouse tumor tail vein injection lung metastasis model was established using the liver cancer cell lines (LM9 Vector and LM9OE-PIPOX, SK-Hep1 sgNC and SK-Hep1 sgPIPOX-2) stably overexpressing or knocking out PIPOX constructed in Example 3. The experimental scheme is as follows:
[0075] Construction of a lung metastasis model by tail vein injection of tumor in nude mice: The in vivo animal experiment was approved by the Animal Ethics Committee of West China Hospital, Sichuan University. Five-week-old male SPF-grade BALB / c nude mice were used. The LM9 Vector and LM9 OE-PIPOX cell lines, as well as the SK-Hep1 sgNC and SK-Hep1 sgPIPOX-2 cell lines were used to construct a lung metastasis model by tail vein injection of tumor. Cells in the logarithmic growth phase were taken, counted, and the concentration of the cell suspension was adjusted (cells were resuspended and diluted with PBS). The concentration of the LM9 cell line was adjusted to 2×10 7 cells / mL, and the SK-Hep1 cell line was adjusted to 1×107 / mL. Take 100μL of cell suspension and slowly inject it into the tail vein of nude mice, 5 mice in each group. One week after inoculation, inoculate again (repeat all the above steps). About 6 weeks after inoculation, the growth of lung metastases in nude mice was detected by in vivo imaging, that is, after intraperitoneal injection of D-luciferin, the tumor metastasis was observed by IVIS@Lumina II system. After the test, the nude mice were killed and the lung tissues were removed and fixed with 4% paraformaldehyde for subsequent HE staining.
[0076] The experimental results are as follows Figure 5 As shown in the figure, compared with the respective negative control groups, the bioluminescent signal of the lungs of nude mice in the PIPOX overexpression group was significantly weakened (P<0.05), and H&E staining of lung tissue sections showed that the number of lung metastases was significantly reduced (P<0.05); while the bioluminescent signal of the lungs of nude mice in the PIPOX knockout group was significantly enhanced (P<0.05), and H&E staining of lung tissue sections showed that the number of lung metastases was significantly increased (P<0.05). It can be seen that at the in vivo level, overexpression of PIPOX can inhibit the lung metastasis of liver cancer, and knockout of PIPOX can promote the lung metastasis of liver cancer. Therefore, PIPOX can be used as a therapeutic target for inhibiting liver cancer metastasis and applied to the treatment of liver cancer.
[0077] [Example 6]
[0078] In this example, real-time fluorescence quantitative PCR and protein immunoblotting were used to detect changes in mRNA and protein expression levels of markers related to the epithelial-mesenchymal transition (EMT) process in liver cancer cells with overexpression and knockout of PIPOX, respectively.
[0079] The experimental plan is as follows:
[0080] (1) RT-qPCR: Total RNA of cells was extracted using a cell RNA extraction kit according to the manufacturer's instructions, and reverse transcribed to synthesize cDNA. RT-qPCR reaction was performed using ChamQTM SYBR@qPCR Master Mix. U6 was set as the internal reference gene, and finally 2 -ΔΔCt The relative mRNA expression was calculated by RT-qPCR. The RT-qPCR primer sequences are shown in Table 2.
[0081] Table 2
[0082]
[0083] Specifically, after extracting total RNA, reverse transcription is performed to synthesize cDNA. The PCR reaction system is prepared on ice (taking a 20 μL system as an example), and after the preparation is completed, the cDNA template obtained by reverse transcription is added. The PCR reaction system is:
[0084]
[0085] The reaction conditions include:
[0086] Step 1: Pre-denaturation
[0087] 95°C, 5 minutes;
[0088] Step 2: PCR reaction (40 cycles)
[0089] 95°C, 20 seconds; 60°C, 20 seconds; 72°C, 20 seconds.
[0090] Step 3: Melting curve analysis
[0091] 65°C, 5 seconds; 95°C, 5 seconds.
[0092] Quantitative analysis was performed after PCR amplification. The formula for calculating the relative expression of the target gene was: 2-△△Ct=2-
(△Ct)Test-(△Ct)Control
[0093] (2) Protein immunoblotting:
[0094] Step 1: Lyse cells, extract total protein, and prepare protein samples;
[0095] Step 2: Take out the protein sample and place it on ice to dissolve, add Loading Buffer (5×) at a ratio of 4:1, mix thoroughly, boil at 100℃ for 5 minutes, and cool to room temperature;
[0096] Step 3: Place the glass plate with glue into the electrophoresis tank, add electrophoresis solution, and slowly pull out the comb vertically;
[0097] Step 4: Use a micropipette to add the cooled protein sample to the loading well. After loading, add protein pre-stained markers to the loading wells on both sides for marking.
[0098] Step 5: Connect the power supply, constant voltage 80V, when the strip enters the separation gel, adjust the voltage to 120V until the strip runs to the bottom of the separation gel;
[0099] Step 6: Prepare the transfer container, pour the transfer buffer into it, and soak the clean filter paper and sponge in the transfer solution;
[0100] Step 7: Cut the PVDF membrane into appropriate size and activate it by immersing it in methanol for 30 seconds;
[0101] Step 8: Place the transfer plate in the transfer solution, pry open the glass plate, with the black side facing down, and put in the sponge, filter paper, gel, PVDF membrane, filter paper, and sponge in order. After removing the bubbles, clamp the transfer plate and put it in the transfer tank. Pour the transfer solution to submerge the transfer tank, and cover it with the lid.
[0102] Step 9: Place the tank in a foam box and cover it with ice, and transfer the membrane at a constant current of 250 mA (calculate the transfer time at 1 KD / min);
[0103] Step 10: After the transfer is completed, take out the PVDF membrane, immerse it in the blocking solution, and block it at room temperature for 2 hours at a low speed on a horizontal shaker;
[0104] Step 11: After blocking, remove the PVDF membrane, cut the target fragment according to the marker, put it into the corresponding primary antibody dilution solution (diluted with 5% BSA according to the instructions), and incubate it overnight on a shaker at 4°C;
[0105] Step 12: Recover the primary antibody and wash three times with TBST, 5 minutes each time;
[0106] Step 13: Select the corresponding secondary antibody according to the species of the primary antibody, dilute the secondary antibody with TBST, immerse the membrane in the secondary antibody dilution solution and incubate on a shaker at room temperature for 2 hours;
[0107] Step 14: Discard the secondary antibody and wash three times with TBST, 5 minutes each;
[0108] Step 15: Prepare an appropriate amount of ECL color developing solution, take out the PVDF membrane, add the color developing solution dropwise onto the PVDF membrane to ensure that it is covered, and place it in a chemiluminescence imager for exposure and development.
[0109] The experimental results are as follows Figure 6 As shown in (a), compared with the respective negative control groups, the mRNA expression of E-cadherin in LM9 cells overexpressing PIPOX was significantly upregulated (P<0.05), and the mRNA expression of N-cadherin, vimentin, and Snail was significantly downregulated (P<0.05). Figure 6 As shown in (b), the mRNA expression level of E-cadherin in SK-Hep1 cells after knocking out PIPOX was significantly downregulated (P<0.05), and the mRNA expression levels of N-cadherin, vimentin, and Snail were significantly upregulated (P<0.05).
[0110] Next, further verification was performed by western blotting, and the results were consistent with those of RT-qPCR, that is, compared with the respective negative control groups, the protein expression level of E-cadherin in LM9 cells overexpressing PIPOX was upregulated, and the protein expression levels of N-cadherin, vimentin, and Snail were downregulated. The experimental results are shown in Figure 6 (c). After PIPOX knockout, the protein expression level of E-cadherin in SK-Hep1 cells was downregulated, while the protein expression levels of N-cadherin, vimentin, and Snail were upregulated. The experimental results are shown in Figure 6 (d) Based on the above results, it was confirmed that overexpression of PIPOX can inhibit the EMT process of liver cancer cells, and knockout of PIPOX can promote the EMT process of liver cancer cells.
[0111] [Example 7]
[0112] In this example, based on the conclusion that overexpression of PIPOX can inhibit the EMT process of liver cancer cells, the inhibitory effect of overexpression of PIPOX combined with knockdown of Snail on the migration and invasion of liver cancer cells was analyzed. The experimental scheme is as follows:
[0113] (1) Construction of Snail knockdown liver cancer cell line by siRNA transfection:
[0114] Step 1: The siRNA transfection reagent used in this experiment is GenMute TM siRNA Transfection Reagent, siRNAs were chemically synthesized by Beijing Qingke Biotechnology Co., Ltd. The siRNA target sequences involved in this experiment are shown in Table 3;
[0115] Table 3
[0116]
[0117] siRNA-Snail CCACTCAGATGTCAAGAAGTA
[0118] siRNA-NC TTCTCCGAACGTGTCACGT
[0119] Step 2: Plate the cells in a 6-well plate in advance. When the cell density reaches 50%-70%, siRNA transfection can be performed (the following operations are all based on a 6-well plate as an example);
[0120] Step 3: Centrifuge the siRNA dry powder at 4000 rpm for 1 min to make the dry powder sink completely to the bottom of the tube to prevent loss after opening the lid, add sterilized ddH2O to dissolve, mix thoroughly, and dilute the siRNA solution to a concentration of 5 μM, and place on ice for later use;
[0121] Step 4: Within 30-60 minutes before siRNA transfection, the cells need to be replaced with a new medium. The old medium should be discarded, and the cells should be washed 1-2 times with PBS. The PBS should be discarded, and 1 mL of fresh complete medium containing serum and double antibody should be added to each well. The cells should then be placed in a 37°C cell culture incubator for later use.
[0122] Step 5: Prepare a new sterilized 1.5 mL centrifuge tube and prepare the siRNA transfection system in the tube (the following is the amount per well of a 6-well plate);
[0123] Step 6: First add 20 μL of 5×GenMuteTM siRNA Transfection Buffer and 80 μL of sterilized ddH2O to the centrifuge tube and dilute it to 100 μL of 1×GenMuteTM siRNA Transfection Buffer working solution;
[0124] Step 7: Pipette 10 μL of siRNA solution (containing 50 pmoles siRNA in total) and add it to the above 100 μL of 1×GenMuteTM siRNA Transfection Buffer working solution, and vortex to mix;
[0125] Step 8: Add 4 μL GenMuteTM Reagent to the centrifuge tube and mix well with a pipette;
[0126] Step 9: The centrifuge tube was left to stand at room temperature for 15 minutes to form a transfection complex;
[0127] Step 10: Take out the 6-well plate, add the transfection complex in the centrifuge tube to the culture medium drop by drop, shake gently to mix, and put it back into the 37°C cell culture incubator for transfection;
[0128] Step 11: After overnight culture, replace the medium with fresh complete cell culture medium;
[0129] Step 12: 48 h after transfection, collect cells for Transwell assay.
[0130] (1) Transwell cell migration and invasion assay:
[0131] The above-constructed liver cancer cell lines (including 4 groups of cell lines in total: LM9 Vector + siNC, LM9OE-PIPOX + siNC, LM9 Vector + siSnail, LM9 OE-PIPOX + siSnail) were used to carry out Transwell cell migration and invasion experiments. The specific operation method was the same as the operation process of the Transwell cell migration and invasion experiment in Example 4, and the migration and invasion abilities of each group of cells were detected respectively.
[0132] The experimental results are as follows Figure 7 As shown, overexpression of PIPOX or knockdown of Snail can significantly reduce the migration and invasion of cancer cells, while simultaneous overexpression of PIPOX and knockdown of Snail can reduce the migration and invasion of cancer cells to a greater extent.
[0133] The specific implementation methods described above further illustrate the objectives, technical solutions and beneficial effects of the present invention in detail. It should be understood that the above description is only a specific implementation method of the present invention and is not intended to limit the scope of protection of the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principles of the present invention should be included in the scope of protection of the present invention.
Claims
1. Use of an agent capable of increasing the expression level of PIPOX in the preparation of a drug for treating liver cancer.
2. Use of an agent that can increase the expression level of PIPOX in the preparation of a drug for inhibiting the migration and invasion of liver cancer cells.
3. Use of an agent capable of increasing the expression level of PIPOX in combination with a mesenchymal cell marker inhibitor for preparing a drug for treating liver cancer or a drug for inhibiting the migration and invasion of liver cancer cells, wherein: The interstitial cell marker inhibitor is at least one of siRNA, sgRNA, small molecule inhibitors, and compounds with the interstitial cell marker as a target gene, and the interstitial cell marker is at least one of N-cadherin, vimentin, and Snail.
4. A pharmaceutical composition for treating or inhibiting the migration and invasion of liver cancer cells, characterized in that: The pharmaceutical composition comprises a PIPOX overexpression vector and a pharmaceutically acceptable adjuvant.
5. A pharmaceutical composition for treating or inhibiting the migration and invasion of liver cancer cells according to claim 4, characterized in that: The pharmaceutical composition also includes an inhibitor for inhibiting the expression level of a mesenchymal cell marker, wherein the inhibitor is at least one of siRNA, sgRNA, a small molecule inhibitor, and a compound with the mesenchymal cell marker as a target gene.
6. A pharmaceutical composition for treating or inhibiting the migration and invasion of liver cancer cells according to claim 5, characterized in that: The interstitial cell marker is at least one of N-cadherin, vimentin and Snail.
7. A pharmaceutical composition for treating or inhibiting the migration and invasion of liver cancer cells according to claim 6, characterized in that: The interstitial cell marker is Snail, and the Snail inhibitor is siRNA having a sequence as shown in SEQ ID NO.
1.
8. Use of a reagent for quantitatively detecting PIPOX in the preparation of a product for diagnosing liver cancer or predicting the prognosis of liver cancer.
9. A product for diagnosing liver cancer or predicting the prognosis of liver cancer, the product comprising: A collection unit, used to obtain the expression level of PIPOX; The analysis unit is used to analyze the diagnosis or prognosis prediction results of liver cancer based on the expression level of PIPOX.
10. Use of PIPOX in screening candidate drugs for adjuvant treatment of liver cancer, wherein the use is carried out using in vitro liver cancer cells or tissues.
